Latest News and Press Releases
Want to stay updated on the latest news?
-
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company...
-
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
-
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
-
Dublin, May 20, 2024 (GLOBE NEWSWIRE) -- The "Global Peripheral Nerve Injury Market" report has been added to ResearchAndMarkets.com's offering.The global peripheral nerve injury market is poised...
-
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Spinal Cord Trauma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
-
BRUSSELS, BELGIUM, April 26, 2023 (GLOBE NEWSWIRE) -- Repair and regeneration in the nervous system is a process by which damaged tissue undergoes regrowth or renewal, eventually restoring nervous...
-
TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy...
-
New York, Sept. 02, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Nerve Repair & Regeneration Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
-
New York, Aug. 26, 2019 (GLOBE NEWSWIRE) -- A rising number of peripheral and neurological failures, increasing investments into R&D for the nerve repair and regeneration procedures, a...